|
Abstract Objective: To explore the influence of metformin combined with subcutaneous insulin pump injection on pregnancy outcomes and serum levels of Cystatin C (CysC), Creactive protein (CRP) and betatrophin of pregnant women with gestational diabetes mellitus (GDM). Methods: 126 pregnant women with GDM were selected as research objects from February 2017 to February 2018, and they were divided into the observation group (n=65) and the control group (n=61) by random number table. The women in the control group were treated with subcutaneous injection with insulin pump, while the women in the observation group were treated with metformin combined with insulin pump for subcutaneous injection. The blood sugar index, such as levels of FBG, 2hPG, HbAlc, serum levels of Cys C, CPR, and betatrophin, adverse pregnancy outcomes of pregnant women, and incidence of neonatal complications were compared between the two groups. Results: After treatment, the levels of FBG, 2hPG, HbAlc, Cys C, CPR, and betatrophin of women in the observation group were 3.98±0.93 mmol/L, 5.90±0.70mmol/L, 5.18±0.65%, 0.71±0.15mg/L, 1.43±0.31pg/L, and 572.39±87.61pg/mL, respectively, which were significant lower than those (6.05±1.02mmol/L，9.02±0.85mmol/L，6.07±0.84%, 0.92±0.20 mg/L, 2.16±0.46pg/L, and 703.21±97.82pg/mL, respectively) of women in the control group（P<0.05). The adverse pregnancy outcomes of women in the observation group was 6.15%（4/65）, which was also significant lower than that (37.7%,23/61) of women in the control group（P<0.05）. The incidence of neonatal complications in the observation group was 12.30%（8/65）, which was significant lower than that (37.7%, 23/61) in the control group（P<0.05）. Conclusion: Metformin combined with insulin pump subcutaneous injection can effectively control the blood sugar level of preganet women with GDM, can improve their pregnancy outcomes, can reduce the complication rate of mothers and newborns, and can decrease serum levels of CysC, CRP and betatrophin.
|
